search

IBBL IMIIMI is the world’s biggest public-private partnership in the field of life sciences. The initiative has a budget of €3.3 billion for the period 2014-2020 with which it funds research aiming to speed up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. On 14 December 2018, its first 10 years of funding medical breakthrough will be celebrated by an international conference and networking event taking place in Luxembourg.

IBBL is taking part in two IMI projects, LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) and CANCER-ID (Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood). LITMUS aims to develop and validate highly accurate blood tests and imaging techniques that will allow doctors and researchers to rapidly and easily diagnose the severity of the disease in individual patients and monitor changes in their livers. The objective of CANCER-ID is to develop new, less invasive ways of capturing cancerous cells and cancer genetic material from blood samples and analysing them for clues to what treatment is needed and how well drugs are working. The project focuses initially on specific types of lung and breast cancer.

Luxinnovation discussed with Kristin Kornerup, Project manager at IBBL, about the biobank’s involvement in the projects.

IBBL IMIWhat is IBBL’s contribution to these two IMI projects?

IBBL has been chosen as the central biobank of LITMUS. As such, it will gather all the biological samples currently stored at the other partners’ sites. IBBL will also serve as the central collection and storage site for the samples that will be freshly collected for the LITMUS project from at least 1,500 patients across Europe. We will store blood, plasma, serum, DNA, RNA, urine, stool and liver biopsies and create a catalogue of the samples and associated data to be made available to the research community.

In CANCER-ID, IBBL contributes to the validation of laboratory methods, the development of standard operating procedures and the development of a proficiency testing programme.

 

What kind of results are you aiming for? How do they translate to Luxembourg?

The aim of CANCER-ID is to validate the use of specific blood-based biomarkers for the early diagnosis of cancer. In addition, these could help in monitoring the efficacy of treatment, as well as helping clinicians with choosing the right treatment for the right patient at the right time.

At the national level, IBBL will bring its expertise in biobanking and biomarker validation to the EU consortia, thus increasing Luxembourg’s visibility and strengthening its reputation as a centre of excellence among internationally-renowned universities, SMEs and pharmaceutical companies. Ultimately, the results of the projects will translate into better healthcare both for European and Luxembourgish patients.

What does the IMI participation bring to IBBL?

Given the competitiveness of IMI grants, IBBL is very proud to have been selected as a partner of these two prestigious consortia. Our participation in the projects further confirms our international reputation as a reliable, quality-driven biobank and a valuable partner. Our involvement in two IMI grants has contributed to strengthening our network of partners and our growing portfolio of European and international projects.

Pictures: © IBBL

Luxinnovation is the National Contact Point for Horizon 2020, the European framework programme for research and innovation. Building on our decade-long experience of EU funding programmes, we are able to respond to questions on where to get up-to-date information on programmes and calls for project proposals, what programmes are the most suitable for you or where and how to find European partners.

Read more

35 years at the service of innovation in Luxembourg

15-11-2019

In the presence of His Royal Highness the Grand Duke, Luxinnovation, the national agency for the promotion of innovation, celebrated its 35th anniversary at the
Athénée de Luxembourg.
Read more

Public consultation on European Institutionalised partnerships – Closing on 6 November

04-11-2019

The consultation on European Institutionalised partnerships will soon close on 6th November 2019, so hurry up and have your say. 
Read more

A year connecting Horizon 2020 and Horizon Europe

17-10-2019

Benjamin Questier, Strategic Advisor & Head of European R&D and Innovation Support at Luxinnovation, reviews the successes and opportunities offered by the European framework programme Horizon 2020 and also provides insight into the forthcoming Horizon Europe programme.
Read more

Co-designing the EU’s next framework programme

27-09-2019

Horizon Europe, the EU’s next framework for research and innovation, will be launched in 15 months’ time and run until the end of 2027. Interested stakeholders now have the opportunity to provide their input on the content and implementation of the programme.
Read more

Research and innovation staff exchange

27-09-2019

Are you in search of a funding programme for your research and innovation project? The Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) promotes cross-border and cross-sector collaboration between research and market within Europe and beyond.
Read more

All news

Fermer